Conference Call with Dr. Lal Pathlabs Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Healthcare Services firm Dr. Lal Pathlabs declares Q3FY22 result: Consolidated Performance Highlights: Q3 FY 2021-22 vs Q3 FY 2020-21 Revenue: Rs 496.9 Cr, a growth of 9.8% Normalised EBITDA at Rs 141.8 Cr with margin at 28.5% PBT at Rs 81.5 Cr with margin at 16.4%, and PAT Rs 58.2 Cr with margin at 11.7% Covid and Allied contributed 11.8% to Revenue in Q3 FY22 with 5.8 lacs RTPCR tests Normalised EBITDA (after adjustment for stock based compensation, CSR & One time acquisition cost) for Q3 FY22 is at Rs. 141.8 Cr (margins 28.5%) Vs Rs 144.6 Cr in the same quarter last year PBT is at Rs 81.5 Cr in Q3 FY22 (Normalised PBT* at Rs 112.8 Cr, margins 22.7%) vs Rs 128.9 Cr. in Q3 last year Profit after Tax in Q3 FY22 (Normalised PAT* at Rs 83.6 Cr, margins 16.8%) at Rs. 58.2 Cr as compared to Rs 95.9 Cr in Q3 last year Result PDF
Highlights Revenue: Rs 498.4 Cr, a growth of 15.4% Normalised EBITDA at Rs 152.2 Cr with margin at 30.5% PBT at Rs 130.7 Cr with margin at 26.2%, and PAT Rs 96.3 Cr with margin at 19.3% Operating Revenue increased by 15.4% in Q2 FY22 to Rs. 498.4 Cr vs Rs 431.9 Cr in Q2 FY21 Covid and Allied contributed 10.1% to Revenue in Q2 FY22 with 4.7 lac RT-PCR tests Normalised EBITDA (after adjustment for stock based compensation & CSR cost) for Q2 FY22 is at Rs. 152.2 Cr vs Rs 134.7 Cr in the same quarter last year PBT is at Rs 130.7 Cr in Q2 FY22 vs Rs 116.6 Cr. in Q2 last year Profit after Tax in Q2 FY22 at Rs. 96.3 Cr as compared to Rs 87.1 Cr in Q2 last year “Our joining hands with Suburban Diagnostics is a significant step in LPL’s endeavor to expand our footprint in Western India. I am confident that our combined strengths and a similar DNA of both the companies- led by doctor promoters, will lead to new heights in serving our customers across Western India.” (Hony) Brig. Dr Arvind Lal, Padma Shri, Executive Chairman, Dr Lal PathLabs Limited “Suburban Diagnostics transaction is in line with our stated strategy of driving growth through inorganic route especially in West and South regions. This transaction has a strategic significance for us from a long term stand point.” Dr. Om Manchanda, Managing Director, Dr Lal PathLabs Limited Result PDF